Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Apr;17(2):173-6.
doi: 10.5863/1551-6776-17.2.173.

The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis

Rachel F Eyler  1 , Kristin C Klein, Bruce A Mueller
Affiliations
Case Reports

The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis

Rachel F Eyler et al. J Pediatr Pharmacol Ther. 2012 Apr.

Abstract

This report details the pharmacokinetics of oseltamivir and oseltamivir carboxylate following administration of high-dose oseltamivir in a critically ill child receiving extracorporeal membrane oxygenation (ECMO) and continuous venovenous hemodialysis (CVVHD). A 6-year-old critically ill male patient suffering from a presumed viral illness was transferred to our institution's pediatric intensive care unit from an outside hospital after developing respiratory failure and cardiomegaly. ECMO and oseltamivir therapy were initiated upon admission, and CVVHD was started on hospital day 3. Pharmacokinetic sampling occurred at an oseltamivir dose of approximately 4 mg/kg on hospital day 6. The patient's oseltamivir and oseltamivir carboxylate area under the plasma concentration time curves for the 12-hour dosing interval (AUC(0-12)) were 30.5 and 905 ng/mLhr, respectively. Drug clearance by CVVHD was 31.6 mL/min for oseltamivir and 26.9 mL/min for oseltamivir carboxylate. Pre- and postoxygenator oseltamivir and oseltamivir carboxylate plasma concentrations did not differ substantially. The patient's oseltamivir carboxylate plasma concentrations remained well above the reported mean 50% inhibitory concentration for 2009 pandemic H1N1 virus. However, despite receiving twice the standard dose of oseltamivir, the oseltamivir carboxylate AUC(0-12) in our patient was less than that reported in noncritically ill pediatric subjects. The reduced oseltamivir carboxylate AUC(0-12) found in our patient was most likely due to decreased drug absorption.

Keywords: continuous renal replacement therapy; dialysis; extracorporeal membrane oxygenation; influenza; oseltamivir.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Genentech. Tamiflu prescribing information. Genentech, USA; South San Francisco, CA: 2011. http://www.gene.com/gene/products/information/tamiflu/pdf/pi.pdf. Accessed July 14, 2012.
    1. Wildschut ED, Ahsman MJ, Allegaert K, et al. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010;36(12):2109–2116. - PMC - PubMed
    1. Mulla H, McCormack P, Lawson G, et al. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology. 2003;99(2):275–282. - PubMed
    1. Wildschut ED, de Hoog M, Ahsman MJ, et al. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One. 2010;5(6) :e10938. - PMC - PubMed
    1. Eyler RF, Heung M, Pleva M, et al. Oseltamivir and Oseltamivir Carboxylate Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis [abstract A1–1999] Proceedings of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA. September 15, 2010.

Publication types

LinkOut - more resources